A Multicenter, Randomized, Double-Blind Trial in Subjects With Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)
A Multicenter, Randomized, Double-Blind Trial in Subjects With Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)
The purpose of study is to compare the efficacy and safety of ONO-4538 in combination with carboplatin, paclitaxel, and bevacizumab (ONO-4538 group) to placebo in combination with carboplatin, paclitaxel, and bevacizumab (placebo group) in chemotherapy-naïve subjects with stage IIIB/IV or recurrent non-squamous non-small cell lung cancer unsuitable for radical radiation in a multicenter, randomized, double-blind study.
Inclusion Criteria:
Exclusion Criteria:
Higashiibaraki, Ibaraki, Japan
Kitaadachi-gun, Saitama, Japan
Sunto-gun, Shizuoka, Japan
Bunkyo-ku, Tokyo, Japan
Bunkyo-ku, Tokyo, Japan
Bunkyō-Ku, Tokyo, Japan
Chuo-ku, Tokyo, Japan
Chuo-ku, Tokyo, Japan
Itabashi-ku, Tokyo, Japan
Koto-ku, Tokyo, Japan
Minato-ku, Tokyo, Japan
Mitaka-shi, Tokyo, Japan
Shinjuku-Ku, Tokyo, Japan
Shinjuku-Ku, Tokyo, Japan
Shinjuku-ku, Tokyo, Japan